ReviewDiscover oncology2025
Recent advances in the study of FAT family genes in lung cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Analysis of mRNA and microRNA Expression in Corneal Impression Cytology Samples from Patients withInternational journal of molecular sciences · 2026Article
- FAT2 inhibits breast cancer cell migration, invasion, and epithelial-mesenchymal transition through transcriptional upregulation of CLDN19.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The FAT atypical cadherin (FAT) gene family comprises FAT atypical cadherin 1 (FAT1), 2 (FAT2), 3 (FAT3), and 4 (FAT4). These transmembrane adhesion proteins are essential for regulating cell polarity, adhesion, and migration, and are involved in multiple signaling transduction pathways. With the advancement of tumor genomics research, the mutation, expression, and functional regulation of FAT in various cancer types have been elucidated, particularly in non-small cell lung cancer, where FAT has significant biological implications and promising clinical applications. FAT1, a frequently mutated member of the family, participates in remodeling the immune microenvironment via the Wnt/β-catenin, Hippo, and transforming growth factor-beta (TGF-β) pathways. It also influences immune cell infiltration, immune checkpoint expression, and tumor mutational burden, thereby affecting the efficacy of immunotherapy. FAT2 influences cell migration and immune response by modulating cytoskeletal dynamics and the expression of immunochemokines. The non-coding RNA circular RNA FAT3 (circFAT3) may contribute to tumor growth and metastasis. FAT4, a major upstream regulator of the Hippo signaling pathway, inhibits Yes-associated protein/transcriptional coactivator with PDZ-binding motif, maintains cell polarity, and plays multiple roles by regulating the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathways and promoting anti-immune escape. This study comprehensively integrated and analyzed research results on the characteristics of the FAT gene family in lung cancer, focusing on its mutations, signaling pathways, and immunological roles, as well as its clinical significance in terms of prognosis. This study provides theoretical support and references for the development of targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.